BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19717092)

  • 1. Is there a role for second-line chemotherapy in advanced gastric cancer?
    Wesolowski R; Lee C; Kim R
    Lancet Oncol; 2009 Sep; 10(9):903-12. PubMed ID: 19717092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
    Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Second-line treatment for metastatic or locally advanced gastric cancer].
    Li KC; Cheng SY; Du J; Li J
    Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):721-724. PubMed ID: 27784452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
    Lim JY; Cho JY; Paik YH; Lee DK; Lee SI; Park HJ; Lee SJ; Lee KS; Yoon DS; Choi SH
    Oncology; 2007; 73(1-2):2-8. PubMed ID: 18332648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line chemotherapy for advanced gastric cancer in Korea.
    Baek SK; Kim SY; Jeong JH; Cho KS; Yoon HJ
    Gastric Cancer; 2012 Oct; 15(4):345-54. PubMed ID: 22410800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metastatic gastric cancer: does second-line chemotherapy make sense?].
    Breithaupt K; Thuss-Patience PC
    Dtsch Med Wochenschr; 2010 Sep; 135(38):1872-6. PubMed ID: 20842609
    [No Abstract]   [Full Text] [Related]  

  • 8. Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.
    Seo MD; Lee KW; Lim JH; Yi HG; Kim DY; Oh DY; Kim JH; Im SA; Kim TY; Lee JS; Bang YJ
    Jpn J Clin Oncol; 2008 Sep; 38(9):589-95. PubMed ID: 18772169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug therapy for inoperable gastric cancer: current possibilities and perspectives of development].
    Volkov NM; Moiseenko VM
    Vopr Onkol; 2007; 53(4):383-92. PubMed ID: 17969398
    [No Abstract]   [Full Text] [Related]  

  • 10. Palliative chemotherapy for advanced gastric cancer.
    Wöhrer SS; Raderer M; Hejna M
    Ann Oncol; 2004 Nov; 15(11):1585-95. PubMed ID: 15520058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
    Lee JL; Ryu MH; Chang HM; Kim TW; Yook JH; Oh ST; Kim BS; Kim M; Chun YJ; Lee JS; Kang YK
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):631-7. PubMed ID: 17520252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy of advanced gastric cancer.
    Rivera F; Vega-Villegas ME; López-Brea MF
    Cancer Treat Rev; 2007 Jun; 33(4):315-24. PubMed ID: 17376598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of second-line chemotherapy for advanced gastric adenocarcinoma.
    Wilson D; Hiller L; Geh JI
    Clin Oncol (R Coll Radiol); 2005 Apr; 17(2):81-90. PubMed ID: 15830569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
    Pozzo C; Barone C
    Oncologist; 2008 Jul; 13(7):794-806. PubMed ID: 18614586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
    Kim HS; Kim HJ; Kim SY; Kim TY; Lee KW; Baek SK; Kim TY; Ryu MH; Nam BH; Zang DY
    Ann Oncol; 2013 Nov; 24(11):2850-4. PubMed ID: 23942775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced disease and new drugs.
    Frustaci S; Buonadonna A; La Mura N; Berretta M; De Paoli A
    Suppl Tumori; 2003; 2(5):S48-50. PubMed ID: 12914391
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.
    Farhat FS; Kattan J; Ghosn MG
    Expert Rev Anticancer Ther; 2010 Apr; 10(4):541-8. PubMed ID: 20397919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geographic differences in approach to advanced gastric cancer: Is there a standard approach?
    Kim R; Tan A; Choi M; El-Rayes BF
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):416-26. PubMed ID: 23764501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.